MedTrace Logo

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

NCT02345265 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-30

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Fallopian Tube Carcinoma
  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube Serous Adenocarcinoma
  • Ovarian Carcinoma
  • Ovarian High Grade Endometrioid Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Primary Peritoneal Carcinoma
  • Primary Peritoneal Endometrioid Adenocarcinoma
  • Primary Peritoneal Serous Adenocarcinoma

Interventions

PROCEDURE

Biopsy Procedure

Undergo biopsy of tumor

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cediranib Maleate

Given PO

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography Test

Undergo echocardiogram

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI scan

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Olaparib

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Joyce F Liu · Dana-Farber - Harvard Cancer Center LAO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-23
Primary Completion
2022-07-07
Completion
2027-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02345265 on ClinicalTrials.gov